FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect.

Zhiwei YaoYu XiaoWen LiShuhui KongHailong TuSiwei GuoZiyi LiuLushun MaRuifeng QiaoSong WangMiao ChangXiaoxu ZhaoYuan ZhangLei XuDaqing SunXiaolong Fu

Published in: Journal of the Association for Research in Otolaryngology : JARO (2024)

Collectively, these results showed that FDA-approved Ted protected HCs from cisplatin-induced HC loss by inhibiting ERK phosphorylation, indicating its potential as a candidate for preventing cisplatin ototoxicity in clinical settings.

Keyphrases

drug administration
signaling pathway
hearing loss
protein kinase